CA2879796A1 - Novel pyridine derivatives - Google Patents

Novel pyridine derivatives Download PDF

Info

Publication number
CA2879796A1
CA2879796A1 CA2879796A CA2879796A CA2879796A1 CA 2879796 A1 CA2879796 A1 CA 2879796A1 CA 2879796 A CA2879796 A CA 2879796A CA 2879796 A CA2879796 A CA 2879796A CA 2879796 A1 CA2879796 A1 CA 2879796A1
Authority
CA
Canada
Prior art keywords
chloro
pyridin
pyrrolidine
amide
cyano
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2879796A
Other languages
English (en)
French (fr)
Inventor
Lilli Anselm
David Banner
Wolfgang Haap
Bernd Kuhn
Thomas Luebbers
Jens-Uwe Peters
Beat SPINNLER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46851300&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2879796(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CA2879796A1 publication Critical patent/CA2879796A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
CA2879796A 2012-08-21 2013-08-19 Novel pyridine derivatives Abandoned CA2879796A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12181247 2012-08-21
EP12181247.3 2012-08-21
PCT/EP2013/067218 WO2014029722A1 (en) 2012-08-21 2013-08-19 Novel pyridine derivatives

Publications (1)

Publication Number Publication Date
CA2879796A1 true CA2879796A1 (en) 2014-02-27

Family

ID=46851300

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2879796A Abandoned CA2879796A1 (en) 2012-08-21 2013-08-19 Novel pyridine derivatives

Country Status (24)

Country Link
US (1) US9409882B2 (enExample)
EP (1) EP2888244A1 (enExample)
JP (1) JP2015530997A (enExample)
KR (1) KR20150044947A (enExample)
CN (1) CN104583198A (enExample)
AR (1) AR092172A1 (enExample)
AU (1) AU2013305102A1 (enExample)
BR (1) BR112015003217A2 (enExample)
CA (1) CA2879796A1 (enExample)
CL (1) CL2015000354A1 (enExample)
CO (1) CO7200259A2 (enExample)
CR (1) CR20150073A (enExample)
EA (1) EA025166B1 (enExample)
HK (1) HK1206716A1 (enExample)
IL (1) IL237128A0 (enExample)
IN (1) IN2015DN00962A (enExample)
MA (1) MA37893A1 (enExample)
MX (1) MX2015002026A (enExample)
PE (1) PE20150995A1 (enExample)
PH (1) PH12015500262A1 (enExample)
SG (1) SG11201500900YA (enExample)
TW (1) TW201412728A (enExample)
WO (1) WO2014029722A1 (enExample)
ZA (1) ZA201500625B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3419970T1 (sl) * 2016-02-26 2020-04-30 F. Hoffmann-La Roche Ag Novi pirolidinski derivati
TWI764976B (zh) 2017-01-24 2022-05-21 日商安斯泰來製藥股份有限公司 取代苯基二氟甲基之脯胺酸醯胺化合物
WO2026032128A1 (en) * 2024-08-05 2026-02-12 Biofront Therapeutics (Beijing) Co., Ltd. Cathepsin l inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9903610D0 (sv) 1999-10-06 1999-10-06 Astra Ab Novel compounds II
WO2006073361A1 (en) 2005-01-06 2006-07-13 Astrazeneca Ab Novel pyridine compounds
CN101370805B (zh) 2006-01-24 2011-04-27 埃科特莱茵药品有限公司 吡啶衍生物
EP2164840A2 (en) * 2007-05-09 2010-03-24 Vertex Pharmaceuticals Incorporated Modulators of cftr
BRPI0820203A2 (pt) 2007-11-30 2015-06-16 Hoffmann La Roche Compostos de pirrdina, processo para a sua preparação, composição farmacêutica que os compreende, uso de composto e método para o tratamento e/ou profilaxia de diabetes mellitus do tipo ii e outras enfermidades
CN101965345B (zh) 2008-03-06 2014-05-28 埃科特莱茵药品有限公司 吡啶化合物
MX2011011094A (es) 2009-04-20 2011-11-04 Hoffmann La Roche Derivados de prolina como inhibidores de catepsina.
US8394834B2 (en) * 2009-08-25 2013-03-12 Hoffman-La Roche Inc. Pyrrolidines as NK3 receptor antagonists
JP6130383B2 (ja) 2011-09-30 2017-05-17 エンドゥ ファーマシューティカルズ，インコーポレイティド ピリジン誘導体

Also Published As

Publication number Publication date
KR20150044947A (ko) 2015-04-27
PE20150995A1 (es) 2015-06-29
US20150307472A1 (en) 2015-10-29
CO7200259A2 (es) 2015-02-27
MA37893A1 (fr) 2017-08-31
IN2015DN00962A (enExample) 2015-06-12
EA201590363A1 (ru) 2015-06-30
IL237128A0 (en) 2015-03-31
TW201412728A (zh) 2014-04-01
SG11201500900YA (en) 2015-03-30
CN104583198A (zh) 2015-04-29
EA025166B1 (ru) 2016-11-30
AU2013305102A1 (en) 2015-02-12
EP2888244A1 (en) 2015-07-01
CL2015000354A1 (es) 2015-10-23
US9409882B2 (en) 2016-08-09
AR092172A1 (es) 2015-03-25
HK1206716A1 (en) 2016-01-15
ZA201500625B (en) 2016-08-31
JP2015530997A (ja) 2015-10-29
BR112015003217A2 (pt) 2017-07-04
CR20150073A (es) 2015-03-13
MX2015002026A (es) 2015-06-05
PH12015500262A1 (en) 2015-03-30
WO2014029722A1 (en) 2014-02-27

Similar Documents

Publication Publication Date Title
US8729061B2 (en) Pyrrolidine derivatives
CA2859928A1 (en) Novel pyrrolidine derivatives
US9409882B2 (en) Pyridine derivatives
US10689339B2 (en) Pyrrolidine derivatives
US8822505B2 (en) Azetidine derivatives
BR112018070451B1 (pt) Composto derivado de pirrolidina, composição farmacêutica e uso deste
HK1261759B (en) Novel pyrrolidine derivatives
TW201336837A (zh) 新穎氮雜環丁烷衍生物

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20170821